Age at Menarche and Type 2 Diabetes Risk

  • Cathy E. Elks
    Medical Research Council Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.
  • Ken K. Ong
    Medical Research Council Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.
  • Robert A. Scott
    Medical Research Council Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.
  • Yvonne T. van der Schouw
    Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands
  • Judith S. Brand
    Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands
  • Petra A. Wark
    Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, St. Mary’s Campus, Norfolk Place, London, U.K.
  • Pilar Amiano
    Public Health Division of Gipuzkoa, Basque Government, San Sebastian, Spain
  • Beverley Balkau
    INSERM, CESP Centre for Research in Epidemiology and Population Health, U1018: Epidemiology of Diabetes, Obesity, and Chronic Kidney Disease Over the Life Course, Villejuif Cedex, France
  • Aurelio Barricarte
    Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública), Madrid, Spain
  • Heiner Boeing
    Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Nuthetal, Germany
  • Ana Fonseca-Nunes
    Department of Epidemiology, Nutrition, Environment, and Cancer Unit, Catalan Institute of Oncology, L'Hospitalet de Lolgbregat, Barcelona, Spain
  • Paul W. Franks
    Department of Clinical Sciences, Clinical Research Center, Skåne University Hospital, Lund University, Malmö, Sweden
  • Sara Grioni
    Fondazione IRCCS Istituto Nazionale Tumori Milan, Via Venezian, Milan, Italy
  • Jytte Halkjaer
    Danish Cancer Society Research Center, Copenhagen, Denmark
  • Rudolf Kaaks
    Division of Cancer Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany
  • Timothy J. Key
    Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, U.K.
  • Kay Tee Khaw
    Department of Public Health and Primary Care, University of Cambridge, Addenbrooke's Hospital, Cambridge, U.K.
  • Amalia Mattiello
    Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy
  • Peter M. Nilsson
    Department of Clinical Sciences, Clinical Research Center, Skåne University Hospital, Lund University, Malmö, Sweden
  • Kim Overvad
    Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark
  • Domenico Palli
    Molecular and Nutritional Epidemiology Unit, ISPO Ponte Nuovo, Florence, Italy
  • J. Ramón Quirós
    Consejería de Sanidad, Public Health Directorate, Oviedo-Asturias, Spain
  • Sabina Rinaldi
    International Agency for Research on Cancer, Lyon Cedex, France
  • Olov Rolandsson
    Department of Public Health and Clinical Medicine, Umeå University, Family Medicine, Umeå University, Umeå, Sweden
  • Isabelle Romieu
    International Agency for Research on Cancer, Lyon Cedex, France
  • Carlotta Sacerdote
    Center for Cancer Prevention (CPO-Piemonte), Turin, Italy
  • María-José Sánchez
    Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública), Madrid, Spain
  • Annemieke M.W. Spijkerman
    National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
  • Anne Tjonneland
    Danish Cancer Society Research Center, Copenhagen, Denmark
  • Maria-Jose Tormo
    Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública), Madrid, Spain
  • Rosario Tumino
    Cancer Registry and Histopathology Unit, “Civile–M.P. Arezzo” Hospital, Ragusa, Italy
  • Daphne L. van der A
    National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
  • Nita G. Forouhi
    Medical Research Council Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.
  • Stephen J. Sharp
    Medical Research Council Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.
  • Claudia Langenberg
    Medical Research Council Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.
  • Elio Riboli
    Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, St. Mary’s Campus, Norfolk Place, London, U.K.
  • Nicholas J. Wareham
    Medical Research Council Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.

抄録

<jats:sec> <jats:title>OBJECTIVE</jats:title> <jats:p>Younger age at menarche, a marker of pubertal timing in girls, is associated with higher risk of later type 2 diabetes. We aimed to confirm this association and to examine whether it is explained by adiposity.</jats:p> </jats:sec> <jats:sec> <jats:title>RESEARCH DESIGN AND METHODS</jats:title> <jats:p>The prospective European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study consists of 12,403 incident type 2 diabetes cases and a stratified subcohort of 16,154 individuals from 26 research centers across eight European countries. We tested the association between age at menarche and incident type 2 diabetes using Prentice-weighted Cox regression in 15,168 women (n = 5,995 cases). Models were adjusted in a sequential manner for potential confounding and mediating factors, including adult BMI.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>Mean menarcheal age ranged from 12.6 to 13.6 years across InterAct countries. Each year later menarche was associated with 0.32 kg/m2 lower adult BMI. Women in the earliest menarche quintile (8–11 years, n = 2,418) had 70% higher incidence of type 2 diabetes compared with those in the middle quintile (13 years, n = 3,634), adjusting for age at recruitment, research center, and a range of lifestyle and reproductive factors (hazard ratio [HR], 1.70; 95% CI, 1.49–1.94; P &lt; 0.001). Adjustment for BMI partially attenuated this association (HR, 1.42; 95% CI, 1.18–1.71; P &lt; 0.001). Later menarche beyond the median age was not protective against type 2 diabetes.</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS</jats:title> <jats:p>Women with history of early menarche have higher risk of type 2 diabetes in adulthood. Less than half of this association appears to be mediated by higher adult BMI, suggesting that early pubertal development also may directly increase type 2 diabetes risk.</jats:p> </jats:sec>

収録刊行物

  • Diabetes Care

    Diabetes Care 36 (11), 3526-3534, 2013-10-15

    American Diabetes Association

被引用文献 (4)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ